Paige Secures Eighth CE Mark For Cancer Identification AI
The Memorial Sloan Kettering spin-out has received CE-IVD and UKCA marks for its artificial intelligence software designed to identify HER2 expression in biopsies.
You may also be interested in...
Paige CEO Andy Moye talked to Medtech Insight about the company’s current offerings in the prostate and breast cancer markets, as well as its future ambitions and general strategy.
Paige’s AI has obtained CE-IVD and UKCA marks, allowing the launch of a breakthrough product that can spot biomarkers from images.
The Paige Prostate is a first-of-its-kind digital prostate imaging analysis software that can act as an extra pair of eyes to help pathologists spot cancer cells.